Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The magic bullets and tuberculosis drug targets.

Ying Zhang1

  • 1Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA. yzhang@jhsph.edu

Annual Review of Pharmacology and Toxicology
|April 12, 2005
PubMed
Summary

Tuberculosis remains a global health threat due to drug resistance and persistent bacteria. New drugs targeting these persistent forms are crucial for effective tuberculosis treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium inhibition of Physarum myosin as examined by the recombinant heavy mero-myosin.

Advances in experimental medicine and biology·2007
Same author

Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2007
Same author

Inositol-1-phosphate synthetase mRNA as a new target for antisense inhibition of Mycobacterium tuberculosis.

Journal of biotechnology·2007
Same author

Screening of common mitochondrial mutations in Chinese patients with mitochondrial encephalomyopathies.

Mitochondrion·2007
Same author

Arbuscular mycorrhizal structure and fungi associated with mosses.

Mycorrhiza·2007
Same author

Tumor anti-angiogenic gene therapy with microencapsulated recombinant CHO cells.

Annals of biomedical engineering·2007

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Tuberculosis (TB) persists as a leading global infectious disease despite advances in chemotherapy.
  • Drug-resistant TB and the HIV pandemic exacerbate the challenge of disease control.
  • Current chemotherapy limitations stem from bacterial persistence and the emergence of resistance.

Purpose of the Study:

  • To review the history and current status of tuberculosis chemotherapy.
  • To examine existing drug targets and explore promising new drug candidates.
  • To identify novel drug targets and strategies for combating persistent tubercle bacilli.

Main Methods:

  • Historical review of tuberculosis drug development.
  • Analysis of current chemotherapy challenges and drug resistance.
  • Discussion of drug targets for both replicating and non-replicating bacilli.
  • Exploration of novel drug candidates and screening methodologies.

Main Results:

  • Current drugs are inadequate against persistent and drug-resistant tuberculosis strains.
  • Understanding drug mechanisms and identifying new targets are essential.
  • Novel drug candidates show promise for future tuberculosis treatment.
  • Conventional drug screening methods fail to address persistent bacilli.

Conclusions:

  • A new generation of drugs targeting persistent tuberculosis bacilli is urgently needed.
  • Effective tuberculosis control requires addressing bacterial persistence and drug resistance.
  • Developing drugs effective against non-replicating bacilli is key to eradicating tuberculosis.

Related Experiment Videos